From professional translators, enterprises, web pages and freely available translation repositories.
anastrozol
anastrozole
Last Update: 2014-11-21
Usage Frequency: 5
Quality:
anastrozol n=104 0a
anastrozole plus herceptin n=103
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
anastrozol plus herceptin n=103
13
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
liek faslodex bol prinajmenšom taký účinný ako anastrozol.
faslodex was at least as effective as anastrozole.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
v pilotnej štúdii (bo16216) sa herceptin a anastrozol podával od dňa 1.
in the pivotal trial (bo16216) herceptin and anastrozole were administered from day 1.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
podávanie v kombinácii s inhibítorom aromatázy v pilotnej štúdii sa herceptin a anastrozol podával od dňa 1.
administration in combination with an aromatase inhibitor in the pivotal trial herceptin and anastrozole were administered from day 1.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
podiel objektívnej reakcie bol u fulvestrantu 19, 2% v porovnaní so 16, 5% pre anastrozol.
the objective response rate for fulvestrant was 19.2% compared with 16.5% for anastrozole.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
podiel objektívnej reakcie bol u faslodexu 250 mg 19,2% v porovnaní so 16,5% pre anastrozol.
the objective response rate for faslodex 250 mg was 19.2% compared with 16.5% for anastrozole.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
celkovo bol fulvestrant v mesačnej dávke 250 mg minimálne rovnako účinný ako anastrozol, čo sa týka času do progresie ochorenia, objektívnej reakcie a doby do úmrtia.
overall, fulvestrant at the 250 mg monthly dose was at least as effective as anastrozole in terms of time to progression, objective response, and time to death.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
celkovo bol faslodex v mesačnej dávke 250 mg minimálne rovnako účinný ako anastrozol, čo sa týka voľného prežitia progresie ochorenia, objektívnej reakcie a doby do úmrtia.
overall, faslodex at the 250 mg monthly dose was at least as effective as anastrozole in terms of progression- free survival, objective response, and time to death.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
podľa výsledkov týchto dvoch štúdií trvalo priemerne 166 dní, kým sa ochorenie zhoršilo v prípade pacientiek užívajúcich 250 mg lieku faslodex raz za mesiac v porovnaní so 126 dňami v prípade pacientiek užívajúcich anastrozol.
looking at the results of the two studies taken together, it took an average of 166 days for the disease to get worse in the patients receiving 250 mg faslodex once a month, compared with 126 days in those taking anastrozole.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
pri použití lieku herceptin v kombinácii s anastrozolom bola stredná doba prežitia bez progresie ochorenia 4, 8 mesiaca v porovnaní s 2, 4 mesiaca u pacientok, ktoré užívali anastrozol samostatne.
when herceptin was used in combination with anastrozole, the median progression-free survival was 4.8 months, compared with 2.4 months in the patients taking anastrozole on its own.
Last Update: 2012-04-12
Usage Frequency: 2
Quality:
v prvých dvoch štúdiách bol liek faslodex rovnako účinný ako anastrozol: čas do zhoršenia ochorenia bol u žien užívajúcich liek faslodex v priemere 5,4 mesiacov v porovnaní so 4,1 mesiacmi v prípade žien užívajúcich anastrozol.
in the first two studies, faslodex was as effective as anastrozole: the women receiving faslodex lived for an average of 5.4 months without their disease getting worse, compared with 4.1 months in those taking anastrozole.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
kombinovaná analýza obidvoch štúdií preukázala, že k progresii došlo u 83% pacientov, ktorým sa podával faslodex, oproti 85% pacientov, ktorí užívali anastrozol.
combined analysis of both trials showed that 83% of patients who received faslodex progressed, compared with 85% of patients who received anastrozole.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
u pacientov užívajúcich liek herceptin v kombinácii s anastrozolom bol takisto čas prežitia bez zhoršenia ich rakoviny dlhší (v priemere 4,8 mesiaca), ako u pacientov, ktorí užívali anastrozol samostatne (v priemere 2,4 mesiaca).
patients receiving herceptin in combination with anastrozole also lived for longer without their cancer getting worse (4.8 months, on average) than those receiving anastrozole alone (2.4 months, on average).
Last Update: 2017-04-26
Usage Frequency: 1
Quality: